Abstract
The conversion of drugs into drug nanoparticles (nano-drugs) represents a feasible method to enhance bioavailability of otherwise sparingly soluble-drugs. Nano-drugs enhance bioavailability through the improvement of dissolution rate and saturation solubility of drugs, by virtue of their small sizes. Nano-drugs available in the market are usually produced by top-down methods, such as wet milling and high pressure homogenization. These conventional top-down methods, however, suffer from high energy and time requirement, as well as wide and inconsistent nano-drug size distribution. Furthermore, commercially available nano-drugs are predominantly crystalline while amorphous nano-drugs are largely neglected despite their propensity to generate high saturation solubility. In this review, nonconventional methods to prepare crystalline and amorphous nano-drugs are discussed, with the bioavailability enhancing characteristics highlighted. Both top-down and bottom-up methods are covered, finally, a sustainability-based perspective comparing amorphous and crystalline nano-drugs is presented.
Keywords: Nanoparticle, nano-crystals, amorphous drug nanoparticles, bioavailability enhancement, top-down, bottom-up.
Current Pharmaceutical Design
Title:Towards Sustainability: New Approaches to Nano-Drug Preparation
Volume: 19 Issue: 35
Author(s): Wean Sin Cheow, Rong Xu and Kunn Hadinoto
Affiliation:
Keywords: Nanoparticle, nano-crystals, amorphous drug nanoparticles, bioavailability enhancement, top-down, bottom-up.
Abstract: The conversion of drugs into drug nanoparticles (nano-drugs) represents a feasible method to enhance bioavailability of otherwise sparingly soluble-drugs. Nano-drugs enhance bioavailability through the improvement of dissolution rate and saturation solubility of drugs, by virtue of their small sizes. Nano-drugs available in the market are usually produced by top-down methods, such as wet milling and high pressure homogenization. These conventional top-down methods, however, suffer from high energy and time requirement, as well as wide and inconsistent nano-drug size distribution. Furthermore, commercially available nano-drugs are predominantly crystalline while amorphous nano-drugs are largely neglected despite their propensity to generate high saturation solubility. In this review, nonconventional methods to prepare crystalline and amorphous nano-drugs are discussed, with the bioavailability enhancing characteristics highlighted. Both top-down and bottom-up methods are covered, finally, a sustainability-based perspective comparing amorphous and crystalline nano-drugs is presented.
Export Options
About this article
Cite this article as:
Cheow Sin Wean, Xu Rong and Hadinoto Kunn, Towards Sustainability: New Approaches to Nano-Drug Preparation, Current Pharmaceutical Design 2013; 19 (35) . https://dx.doi.org/10.2174/1381612811319350002
DOI https://dx.doi.org/10.2174/1381612811319350002 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Hot Topic: Pharmacological and Molecular Targets in Cellular Redox Status Maintenance)
Current Pharmaceutical Design Medical Systemic Therapies for Hepatocellular Carcinoma: Clinical Perspectives and Safety Profile
Current Drug Safety Structural Biology of Bacterial Secretion Systems in Gram-Negative Pathogens- Potential for New Drug Targets
Infectious Disorders - Drug Targets The Recombinant T Cell Receptor Strategy: Insights into Structure and Function of Recombinant Immunoreceptors on the Way Towards an Optimal Receptor Design for Cellular Immunotherapy
Current Gene Therapy Metabolite Quantification in Tumours by Magnetic Resonance Spectroscopy: Objectives, Results and Perspectives
Current Medical Imaging Benefits of Caloric Restriction on Brain Aging and Related Pathological States: Understanding Mechanisms to Devise Novel Therapies
Current Medicinal Chemistry Deubiquitinating Enzyme Inhibitors and their Potential in Cancer Therapy
Current Cancer Drug Targets Predicting Drug Metabolism Induction In Silico
Current Topics in Medicinal Chemistry Hormone Replacement Therapy in Rheumatoid Arthritis
Current Rheumatology Reviews Is Nephrogenic Systemic Fibrosis a Disease of Fibrocytes?
Current Rheumatology Reviews Antioxidant Peptides from Terrestrial and Aquatic Plants Against Cancer
Current Protein & Peptide Science Diagnostic and Therapeutic Nanoparticles in Cardiovascular Diseases
Current Pharmaceutical Design Listeria monocytogenes as a Vector for Anti-Cancer Therapies
Current Gene Therapy The Promising Signatures of Circulating microRNA-145 in Epithelial Ovarian Cancer Patients
MicroRNA Nitric Oxide and Disorders of the Erythrocyte: Emerging Roles and Therapeutic Targets
Cardiovascular & Hematological Disorders-Drug Targets 2´,3´-Dialdehyde of ATP, ADP, and Adenosine Inhibit HIV-1 Reverse Transcriptase and HIV-1 Replication
Current HIV Research Recent Advance in Drug Development of Squamous Cell Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Antimicrobial Drug Interactions in the Critically Ill Patients
Current Clinical Pharmacology INNO-206 (DOXO-EMCH), an Albumin-Binding Prodrug of Doxorubicin Under Development for Phase II Studies
Current Bioactive Compounds Nano Anti-Cancer Drugs: Pros and Cons and Future Perspectives
Current Cancer Drug Targets